Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer
Part of paid clinical trials in Miami, Florida.
- Sponsor
- University of Miami
- Study ID
- NCT00449163
- Phase
- PHASE2
- Status
- Terminated
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 120 Years
- Healthy Volunteers
- Not accepted
Interventions
- Bevacizumab — BIOLOGICAL
- Floxuridine — DRUG
- Irinotecan — DRUG
- Leucovorin — DRUG
Study Details
RATIONALE: Drugs used in chemotherapy, such as irinotecan, floxuridine, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of colorectal cancer by blocking blood flow to the tumor. Giving combination chemotherapy together with bevacizumab may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving combination chemotherapy together with bevacizumab works in treating patients with stage IV colorectal cancer.
Key Dates
- Start date
- Mar 1, 2006
- Status verified
- Apr 2017
- Primary completion
- Mar 31, 2010
- Completion
- Mar 31, 2010
Study Design
- Enrollment
- 25 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Combination Chemotherapy and BevacizumabTreatment cycle is 6 weeks, 2 weeks of consecutive treatment followed by 1 week of rest and 2 weeks of treatment followed by one week of rest. Treatment will be administered weekly, 4 out 6 weeks, on days 1, 8, 22 and 29: * Bevacizumab: 7.5mg/kg via intravenous (IV) infusion on Days 1 and 22; * Irinotecan: 110 mg/m\^2 via IV infusion on Days 1, 8, 22, 29; * Leucovorin: 500 mg/m\^2 via IV infusion on Days 1, 8, 22 and 29; * Floxuridine: 120 mg/kg over continuous infusion on Days 1, 8, 22 and 29.
Primary Outcome Measure
Overall Survival up to 2 Years [ Time Frame: 2 years ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Miami | Miami | Florida | 33136 | - |
Find similar trials in Miami, FL
Related Studies
- ColoCare Study - Colorectal Cancer CohortRecruiting · University of Utah · Los Angeles, California
- A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid TumorsPHASE1/PHASE2 · Recruiting · Merus B.V. · La Jolla, California
- BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid TumoursPHASE1/PHASE2 · Recruiting · Bold Therapeutics, Inc. · Santa Monica, California
- Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid TumorsPHASE1 · Recruiting · Bicara Therapeutics · La Jolla, California